1	COVID-19 in Pakistan: A national analysis of five pandemic waves
2	Short title: COVID-19 waves in Pakistan
2	
3	
4	Taimoor Ahmad <sup>1</sup> , Mujahid Abdullah <sup>1</sup> , Abdul Mueed <sup>1</sup> , Faisal Sultan <sup>2,3</sup> , Ayesha Khan <sup>1</sup> ,
5	Adnan Ahmad Khan <sup>2,4*</sup>
6	
7	<sup>1</sup> Akhter Hameed Khan Foundation, Islamabad, Pakistan
8	<sup>2</sup> Ministry of National Health Services, Regulation and Coordination, Islamabad, Pakistan
9	<sup>3</sup> Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan
10	<sup>4</sup> Research and Development Solutions, Islamabad, Pakistan
11	
12	*Corresponding Author
13	Email: adnan@resdev.org
14	Disclosures:
15	This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation
16	[grant number: INV-025171]. Under the grant conditions of the Foundation, a Creative
17	Commons Attribution 4.0 Generic License has already been assigned to the Author
18	Accepted Manuscript version that might arise from this submission.
19	
20	
21	
22	
23	
24	

## 25 ABSTRACT

#### 26 **Objectives**

The COVID-19 pandemic showed distinct waves where cases ebbed and flowed. While each country had slight, nuanced differences, lessons from each wave with countryspecific details provides important lessons for prevention, understanding medical outcomes and the role of vaccines. This paper compares key characteristics from the five different COVID-19 waves in Pakistan.

#### 32 Methods

We used specific criteria to define COVID-19 waves, and key variables such as COVID-19 tests, cases, and deaths with their rates of change to the peak and then to the trough were used to draw descriptive comparisons. Additionally, a linear regression model estimated daily new COVID-19 deaths in Pakistan.

#### 37 **Results**

Pakistan saw five distinct waves, each of which displayed the typical topology of a complete infectious disease epidemic. The time from wave-start to peak became progressively shorter, and from wave-peak to trough, progressively longer. Each wave appears to also be getting shorter, except for wave 4, which lasted longer than wave 3. A one percent increase in vaccinations increased daily new COVID-19 deaths by 0.10% (95% CI: 0.01, 0.20) in wave 4 and decreased deaths by 0.38% (95% CI: -0.67, -0.08) in wave 5.

#### 45 Conclusion

Each wave displayed distinct characteristics that must be interpreted in the context of the level of response and the variant driving the epidemic. Key indicators suggest that COVID-19 preventive measures kept pace with the disease. Waves 1 and 2 were mainly about prevention and learning how to clinically manage patients. Vaccination started late during Wave 3 and its impact became apparent on hospitalizations and deaths in Wave 5. The impact of highly virulent strains Alpha/B1.1.7 and Delta/B.1.617.2 variants during Wave 3 and milder but more infectious Omicron/BA.5.2.1.7 are apparent.

## 53 INTRODUCTION

In Pakistan, the first case of COVID-19, a novel and little-understood disease, was detected on February 26, 2020. Being a developing country with limited resources, crumbling health infrastructure and low health expenditure (1), Pakistan has no past experience with pandemics and a high burden of communicable diseases (2). As of February 23, 2022, the country had fully vaccinated 43% of its total population (3) and the Omicron variant of COVID-19 was the dominant strain (4). These factors make Pakistan a high-risk country, with a large pool of infection-susceptible people.

The emergence of COVID-19 has arguably been the biggest social and economic disruption in Pakistan in recent history. The pandemic has largely manifested itself in five distinct waves each of which have a rise, plateau and trough in cases, followed by a period of dormancy, after which the incidence of COVID-19 infections begins to rise again. Thus, each individual wave follows a four stage pattern followed by endemicity that has been seen for many infectious disease epidemics (12). Beyond anecdotal observation, there is evidence that this is happening with COVID-19 as well (11). What sets COVID-

19 apart is that after completion of an individual wave, a new one would come along
shortly, rather than much long, for example, annual, recurrences for influenza etc. This
pattern has been seen all across the globe (5–10) with the timing of COVID-19 waves in
different countries broadly coinciding (11).

In this context, current literature on COVID-19 largely focuses on high-income countries during the initial waves (2,13–17), or aggregated at a regional level (5,6). Given the different capacities of countries to manage the pandemic (17), there is a need to explore the characteristics of the subsequent pandemic waves in a developing country context, preferably with granularity of a country-level analysis (2,13–17).

To this end, this paper explores how each of the five waves of the COVID-19 pandemic in Pakistan differed from each other in terms of the total duration of each wave, the time from the start of each wave to its peak, and from its peak to the wave's trough; the length of time in between each wave; as well as key descriptive features like the total number of COVID-19 tests, COVID-19 cases, hospitalizations, deaths from COVID-19, and COVID-19 vaccinations in each wave. Additionally, this study statistically models the key factors that lead to deaths from COVID-19.

## 84 **METHODS**

## 85 Criteria for COVID-19 waves

We begin by retrospectively defining various time periods between 2020 and 2022 as distinct waves, based on existing literature (18). There are a total of 628 observations (daily set of indicators) across these five waves. Based on our criteria, the starting point of each COVID-19 wave is defined as the day with the lowest number of daily new COVID-

- 19 cases preceding a consistent rise in these cases, before the peak of the respective
- 91 COVID-19 wave. The end of each wave is defined as the day with lowest number of daily
- new COVID-19 cases following a 7-day decline; this number also needed to be lower than
- the cases on any of the 7 days that followed it (Table 1).

## 94 Data and variables

- In order to estimate the pattern for COVID-19 throughout the five waves in Pakistan, we
- have used time series of various daily indicators from April 3, 2020 to February 23, 2022,
- 97 which categorized into following themes:
- 98 i) Wave timespan
- 99 ii) COVID-19 tests
- 100 iii) COVID-19 cases
- 101 iv) Test-to-case ratio
- 102 v) COVID-19 positivity
- 103 vi) Hospitalization, treatment, and containment
- 104 vii) COVID-19 deaths
- 105 viii) COVID-19 vaccination
- ix) Policy environment

107 Several variables in the list above were transformed into ratios for the purpose of 108 describing all five COVID-19 waves in Pakistan (Supplementary Table S1).

- 109 The data for all but two of the above variables, second doses of COVID-19 vaccines
- administered and the Oxford Containment and Health Index for COVID-19, was compiled
- 111 from daily national situation reports (Sitreps). These Sitreps are prepared by the National

Emergency Operations Centre (NEOC) in Islamabad, Pakistan. Data in these Sitreps
 have served as the basis for all major COVID-19 policy decisions in Pakistan.

114 The data for second doses of COVID-19 vaccines administered was sourced directly from the National Command & Operation Centre (NCOC), Islamabad, Pakistan, which is the 115 government forum that brings together the ministries of Health and Planning along with 116 117 the military to determine pandemic policy and to coordinate the response. Data for the Oxford Containment and Health Index is taken from a publicly available dataset from the 118 University of Oxford's Blavatnik School of Governance (19). This dataset is compiled by 119 using qualitative information about the non-pharmaceutical interventions (NPIs) in a 120 country and quantifying them into an index. A detailed methodology of the index 121 calculation can be found in a working paper by the Blavatnik school (20). 122

## **Model Specification**

For our model for COVID-19 deaths, we used a linear ordinary least square (OLS) regression carried out using STATA 17. The data as well as the model was divided into five distinct periods, representing the five waves of COVID-19 in Pakistan, as of February 2022. Regression analysis was performed separately on each wave and results were compared with each other to make logical inferences.

Our dependent variable is the Daily New COVID-19 Deaths in Pakistan in logarithmic form ( $LnY_t$ );  $\epsilon_t$  represents the error term capturing the effect of omitted variables. The specification of our linear OLS regression model is as following:

132  $Ln Y_t = \beta_0 + \beta_1 Ln X_{1t} + \beta_2 Ln X_{2t} + \beta_3 X_{3t} + \beta_4 X_{4t} + \beta_5 X_{5t} + \beta_6 X_{6t} + \beta_7 Ln X_{7t} + \epsilon_t$ 

133 We have chosen seven independent variables:

134	i) Log of daily new COVID-19 cases with 21-day delay $(LnX_{1t})$ ;
135	ii) Log of daily new COVID-19 tests with 28-day delay $(LnX_{2t})$ ;
136	iii) The Oxford Containment and Health Index for COVID-19 with 14-day delay $(X_{3t})$ ;
137	iv) Time $(X_{4t})$ ;
138	v) The number of people on ventilators as a proportion of the total admitted $(X_{5t})$ ;
139	vi) The number of people on oxygen as a portion of the total admitted $(X_{6t})$ ;
140	vii) Log of second doses of COVID-19 vaccines administered with 14- day delay (
141	LnX <sub>7t</sub> )
142	Daily new COVID-19 cases were regressed with a 21-day lag, since among those who
143	die from COVID-19 infection, death occurs between a median of 14 days (21) and 25

144 days (average of three weeks) after presenting symptoms (22,23). This is pertinent in the

case of Pakistan, as most of the COVID-19 testing in the country has been symptomatic,

i.e., done when someone develops symptoms of COVID-19 and hence either voluntarily

147 gets tested or is prescribed by a medical professional to do so.

Given the delay for daily new cases, daily new COVID-19 tests were regressed with a delay of 28 days. This delay allows for the time it takes for someone to test positive for COVID-19 and for their symptoms to worsen (for example, by escalating to hospitalization, which takes nearly a week (24) before resulting in death. For vaccination, a 14-day lag was taken, as immunity from vaccines is generally understood to develop two weeks or longer after receiving a shot (25–27).

The Oxford Containment and Health Index is calculated out of 100 which means strict restrictions and a lower value indicate a smaller number of restrictions imposed on the

general population. This variable was regressed with a 14-day lag, as we assume that any new government restrictions will take approximately that long to have any effect. Additionally, the time variable is meant to capture any unmeasured or seasonal effects on COVID-19 deaths in Pakistan, such as an overall rate of increase/ decrease of daily deaths in each wave. We assume the error term is not correlated with any of the independent variable.

Diagnostic tests were performed on the estimated model to ensure the precision of the estimated coefficient: for heteroskedasticity, the Breusch-Pagan test was applied, whereas for serial correlation, the Durbin-Watson test was used. Variance inflation factor (VIF) was calculated for multicollinearity. Dickey-Fuller tests were run for each independent variable in our regression model. All of the variables were found to be stationary, fulfilling an important pre-requisite for our analysis (Table 1).

1	68	
-	00	

Table 1. Augmented Dicky-Fuller tests for unit roots

Variable	Test Statistics	P-Value	H₀: Random Walk
Daily New COVID-19 Deaths	-6.96	0.000	Stationary
Daily New COVID-19 Cases	-3.23	0.018	Stationary
Daily New COVID-19 Tests	-3.94	0.0017	Stationary
Oxford Containment and Health Index	-3.30	0.015	Stationary
Ventilator-admitted Ratio	-5.69	0.000	Stationary
Oxygen-Admitted Ratio	-3.00	0.034	Stationary
Fully Vaccinated People	-2.77	0.003	Stationary

169

## 170 **RESULTS**

## **171** Summary statistics

172 Pakistan experienced five distinct waves from 3<sup>rd</sup> April 2020 till 23<sup>rd</sup> February 2022 (Fig

173 1). The first wave lasted the longest (150 days), while the fifth one was the shortest (83

days). The fourth wave was remarkable for its relatively rapid upslope and a long tail,
while the fifth wave showed the reverse pattern. The duration of each wave of COVID-19
in Pakistan was shorter than the preceding one apart from wave 4. After wave 1, each
wave took less time to reach its peak and took longer to reach its trough apart from wave
5.

179

#### Figure 1. COVID-19 waves and daily new cases

180 The capacity to conduct tests expanded over time from an average of 17,142 tests daily 181 during the first wave to 49,650 during fifth wave. The increase in the daily tests peaked during the fourth wave. The highest average daily number of cases (3147) were observed 182 during the wave 3. The rate of increase of COVID-19 cases was highest during wave 4, 183 184 but the rate of decline in cases after the peak of a wave was fastest during wave 5. Test 185 to case ratio kept on increasing from 15 during the first wave to 57 during the fifth one. While total positivity varied across waves, the rate in daily change of positivity remained 186 relatively unchanged apart from wave 2 and 3, where it is lower as compared to other 187 188 waves (Table 2).

Variables	Wave 1	Wave 2	Wave 3	Wave 4	Wave 5
Dates	April 3, 2020 to August 31, 2020	October 12, 2020 to February 16, 2021	February 23, 2021 to June 22, 2021	July 6, 2021 to November 29, 2021	December 7, 202 to February 23, 2022
Main Variants of Concern (VOCs)	B.1	B.1.36	Alpha/ B1.1.7/ Delta/B.1.617.2	Delta/B.1.617.2	Omicron/BA.5.2.1
Timespan					
Duration of wave (days)	150	128	120	147	83
From wave Start till Peak (days)	72	57	55	31	52
From wave Peak till Trough (days)	78	71	65	116	31

Total tests in the						
entire wave		2,571,244	4,638,219	5,458,041	7,148,130	4,120,909
Avg. Daily New COVID-19 Tests		17,142 (7,931)	36,236 (5,363)	45,484 (8,623)	48,627 (8341)	49,650 (7494)
Rate of Change of Daily New Tests	Up to Peak	380.9	216.5	701.1	836.6	540.4
Rate of Change of Daily New Tests	After Peak	-147.8	-101.0	-504.9	-286.4	-1137.6
COVID-19 Cases Total cases in the entire wave		293,752	246,188	377,668	320,333	221,825
Avg. Daily New COVID-19 Cases		1,958 (1,687)	1,923 (815)	3,147 (1,547)	2,179 (1548)	2,673 (2519)
Rate of Change of Daily New Cases	Up to Peak	93.9	60.9	94.0	161.0	155.9
Rate of Change of Daily New Cases	After Peak	-84.8	-40.0	-84.1	-48.0	-236.4
<b>Test-to-Case Ratio</b> Average Test-to- Case Ratio	Lin	15 (15)	23 (11)	19 (11)	44 (38)	57 (56)
Rate of Change of Test-to-Case Ratio	Up to Peak	4.1	-1.1	-0.4	-1.13	-3.31
Rate of Change of Test-to-Case Ratio	After Peak	84.5	0.3	0.7	1.36	0.99
<b>COVID-19 Positivity</b> Avg. Daily Positivity Ratio during the wave		11.3% (6.4%)	5.2% (1.8%)	6.8% (2.9%)	4.2% (2.6%)	4.9% (4.1%)
Rate of Change of Positivity Ratio	Up to Peak	0.23	0.15	0.10	0.23	0.22
Rate of Change of Positivity Ratio	After Peak	-0.28	-0.10	-0.11	-0.07	-0.30
Hospitalization, Treatment, and Containment Avg. COVID-19 Hospital Admissions		3,817 (2,479)	2,187 (818)	3,970 (1,366)	3,396 (1,776)	1125 (423)
at any given time Avg. Length of Hospital Stay (days)ª		-	13	11	9	5
Avg. Daily New Hospitalization to Daily New Case Ratio (%)		-	8.8 (2.4)	12.4 (3.5)	22.7 (10.7)	15.7 (10.8)
Avg. Daily Recoveries and Hospital Discharges Rate of Change of		1,870 (2,587)	1,746 (1,608)	2,990 (1,454)	2,272 (2,329)	2371 (3797)
Daily Recoveries and Hospital Discharges (non- cumulative)	Up to Peak	23.4	14.3	69.9	202.4	28.76

Rate of Change of						
Daily Recoveries	After					
and Hospital	Peak	-19.8	-6.6	-51.1	-57.7	-0.97
Discharges (non-	I Car					
cumulative)						
Avg. Stable-Admitted		67%	20%	14%	7%	9%
Ratio (%)		(27%)	(6%)	(5%)	(4%)	(4%)
Avg. Patients on		27%	68%			
Oxygen-Admitted		(23%)	(5%)	75% (5%)	83% (2%)	81% (3%)
Ratio (%)		(2370)	(370)			
Avg. Number of		865	1,521			918
Oxygen Beds in Use		(828)	(608)	2,995 (1,080)	2.803 (1,470)	(361)
at any given time		. ,	. ,			. ,
Avg. Oxygen Beds		18%	15%	24%	20%	7%
Utilization Ratio (%)		(11%)	(6%)	(8%)	(10%)	(3%)
Avg. Number of		214	249	429	336	109
Ventilators in Use at		(163)	(90)	(145)	(153)	(36)
any given time		. ,				
Avg. Ventilator-		7%	11%	11%	10%	10%
Admission Ratio (%)		(4%)	(1%)	(0.6%)	(2%)	(1%)
Avg. Ventilators		17%	13%	20%	15%	5%
Utilization Ratio (%)		(10%)	(5%)	(7%)	(7%)	(2%)
COVID-19 Deaths						
Total COVID-19						
deaths in the entire		6,204	5,537	9,423	6,287	1,401
wave						
Avg. Daily New		41.4	43.3	78.5	42.8	16.9
COVID-19 Deaths		(35.3)	(23.0)	(37.4)	(30.6)	(14.3)
Rate of Change of	Up					
Daily New COVID-19	to	1.1	0.5	2.0	1.17	0.45
Deaths	Peak					
Rate of Change of	After				<b>-</b>	/
Daily New COVID-19	Peak	-1.0	0.1	-1.9	-0.44	-0.81
Deaths						
Avg. Daily New		4.4.07	070/	000/	100/	
COVID-19 Deaths -		11%	27%	23%	10%	7%
Daily Hospitalization		(5%)	(13%)	(8%)	(4%)	(4%)
Ratio (%)						
Avg. Daily New		000/	470/	400/	400/	400/
COVID-19 Deaths –		23%	17%	18%	12%	13%
Ventilator in use		(17%)	(6%)	(5%)	(5%)	(8%)
Ratio (%)		0.00/	0.00/	0.00/	0.00/	4 40/
Avg. Death-to-Case Ratio (%)		2.2% (0.8%)	2.3% (1.1%)	2.8% (1.2%)	2.2% (0.8%)	1.1% (1.0%)
COVID-19		(0.0 %)	(1.170)	(1.270)	(0.070)	(1.070)
Vaccination <sup>b</sup>						
Total Administration						
of 2 <sup>nd</sup> doses of		_	_	3,136,386	45,294,948	45,667,572
Vaccine		-	-	0,100,000	70,207,070	-0,001,01Z
Avg. Daily New						
Administration of 2 <sup>nd</sup>		-	_	26,356	308,129	550,212
doses of Vaccine				(25,980)	(172,896)	(186,287)
Policy Environment						
Oxford Containment		58.8	62.4	65.7	58.1	58.6
and Health Index		(7.6)	(4.0)	(6.3)	(9.4)	(5.5)
Standard deviations are reported in parentheses.						

190 Standard deviations are reported in parentheses.

<sup>a</sup>Data for daily new COVID-19 hospitalizations was not available during wave 1.

<sup>b</sup>COVID-19 vaccines were not being administered during waves 1 and 2.

193

194 Hospitalizations were the highest for the first and the third wave and the least for the fifth, 195 whereas duration of hospitalization fell linearly from an initial 13 days during the second wave to 5 days during the fifth. Hospitalizations became more specific over time in that, 196 nearly two third of admitted patients during the first wave were stable, compared to 9% 197 198 during the fifth one. The average stable-admitted ratio decreased continuously from wave 1 to wave 4 but increased slightly in wave 5. The rate at which people recovered from 199 COVID-19 and/or were discharged from hospital was highest in wave 4 and slowest in 200 201 wave 2.

The average Oxygen Beds-Admitted Ratio continuously increasing in each wave, 202 203 reaching its maximum value in wave 4. During the first wave 27% of all admissions required oxygen, 7% needed a ventilator, compared to 81% and 10% respectively during 204 the fifth wave. The average oxygen bed utilization followed a declining trend except for 205 206 the third wave (24%) and was lowest in the fifth wave (7%). The average Ventilators Utilization Ratio shows that all available ventilators were not fully utilized in any of the five 207 waves. The highest ratio was in wave 3 (20%) and the lowest ratio was in wave 5 (5%). 208 209 These two ratios suggest that most critical patients were put on oxygen for recovery and a small proportion of these people were transferred to ventilators. 210

Deaths from COVID-19 were the highest during the third wave at 9,423, which also saw the highest daily number of deaths (78.5) and the highest rate of increase in daily deaths. Average daily deaths to hospitalization peaked during the second wave, while deaths to ventilator use was the highest during the first. Average death to case ratio was the highest

for the third wave but was in the 2.2-2.8% range, with the exception of the fifth wave whenit was 1.1%.

217 Pakistan's vaccination drive started towards the end of wave 2, but full vaccination (i.e.,

people receiving both their doses) did not occur until the beginning of wave 3.

219 Consequently, total and daily new second dose of vaccine administered was highest in

wave 5. Government restrictions, measured by the Oxford Health and Containment Index,

appear to have been comparable in each wave.

## 222 **Regression results**

The results indicate the daily new COVID-19 cases were a statistically significant determinant for daily new deaths in all five waves at 95% CI; a one-percentage increase in COVID-19 cases caused a 0.46- 0.69 % increase in deaths across the five waves (Table 3).

LOG (Daily New	(1)	(2)	(3)	(4)	(5)
COVID-19 Deaths)	Wave 1	Wave 2	Wave 3	Wave 4	Wave 5
LOG (Daily New COVID-19 Cases) – 21-day delay	0.455* [0.289,0.620]	0.685* [0.430,0.939]	0.691* [0.358,1.025]	0.677* [0.542,0.812]	0.506* [0.189,0.823]
LOG (Daily New	0.648*	0.308	-0.162	0.268	0.296
COVID-19 Tests) – 28-day delay	[0.260,1.037]	[-0.179,0.795]	[-0.645,0.322]	[-0.122,0.657]	[-0.771,1.364]
Oxford Containment	-0.027*	-0.009	0.012	0.017	-0.030
and Health Index – 14- day delay	[-0.050, -0.005]	[-0.030,0.012]	[-0.005,0.028]	[-0.006,0.040]	[-0.072,0.013]
Time	-0.035* [-0.042, -0.028]	-0.002 [-0.005,0.001]	-0.009* [-0.016, -0.002]	-0.005* [-0.010, -0.000]	0.011 [-0.008,0.030]
Ventilator-Admitted Ratio	-16.662* [-29.406, -3.918]	0.555 [- 10.098,11.208]	-11.074 [-25.332,3.183]	-14.092* [-19.096, - 9.089]	-15.681* [-27.872, -3.489]

#### Table 3. Ordinary least squares (OLS) regression results for COVID-19 deaths

Oxygen-Admitted Ratio	3.734* [0.788,6.680]	4.413* [1.848,6.979]	0.148 [-5.421,5.718]	0.640 [-2.558,3.838]	2.435 [-4.943,9.814]
LOG (Second doses administered) 14-day delay	-	-	0.073* [0.006,0.139]	0.104* [0.010,0.198]	-0.375* [-0.668, -0.083]
Constant	-1.222 [-4.180,1.736]	-6.707* [-10.447, - 2.967]	3.169 [-1.606,7.945]	-3.417 [-8.348,1.514]	-4.846 [-18.956,9.263]
Observations	122	128	104	147	83
228	*Sig	gnificant at a 95%	6 CI or higher		
229	29 Newey West CI in parentheses				

Newey West CI in parentheses

230

The daily new COVID-19 tests and Oxford Health and Containment Index, which records 231 the presence of government NPIs and restrictions, were both found to be a statistically 232 233 significant determinants of COVID-19 deaths in wave 1. Increasing daily new tests by 1% will reduce the daily deaths by 0.65% (95% CI: 0.26%, 1.04%). While increase in Oxford 234 Health and Containment Index by 1 point will result in 0.03% reduction in daily new deaths 235 (95% CI: -0.05%, -0.005%). 236

The time trend variable is statistically significant in wave 1, wave 3 and wave 4. The 237 coefficients indicate that, on average, daily COVID-19 deaths decreased at a rate of 238 0.04% per day (95% CI: -0.04%, -0.03%) as time passed during wave 1. However, daily 239 new deaths reduced at a rate of 0.01% per day during wave 3 (95% CI: -0.02%, 0.002%) 240 and wave 4 (95% CI: -0.01%, 0.00%). 241

The ventilator to admitted ratio was statistically significant in wave 1, wave 4 and wave 5. 242

243 The coefficient remains negative throughout these three waves and significant at 95% CI.

The coefficients indicates that if ratio of patients on ventilator out of the admitted increases 244

than daily new deaths decrease by 14-17%. 245

Oxygen to admitted ratio is only significant in wave 1 and 2 at 95% CI, where the coefficient is positive. It means that if the ratio of oxygenated patient out of the total admitted increase than daily new deaths due to COVID-19 will increase by approximately 4%.

Lastly, the number of fully vaccinated people came out to be statistically significant in each of the last three waves. During wave 3, COVID-19 deaths increase by 0.07% (95% CI: 0.006,0.14) as percentage of fully vaccinated people increase by one addition percentage. This rate increased to 0.10% (95% CI: 0.006,0.14) during the wave 4. However, in the fifth wave, daily new deaths due to COVID-19 decrease by 0.38% (95% CI: -0.67, -0.08) as fully vaccinated people increases.

## 256 **DISCUSSION**

Pakistan experienced 5 distinct waves from 3<sup>rd</sup> April 2020 to 23<sup>rd</sup> February 2022. Our
analysis reflects both the evolution of Pakistan's response, as well as the differential
impact of different variants of the virus shaped the contours and features of each wave.
Pakistan experienced its initial wave earlier than other South Asian countries including
India, Bangladesh, Sri Lanka and Nepal, while peaks for the subsequent waves coincided
with those in other countries (31).

The upslope, as seen by the rate of change for testing and cases, was always steeper than during the downward slope of a wave. This pattern follows what is known about infectious epidemics in that cases rise quickly, plateau and then fall, slowly to an endemic state where a low ebb of infections persist in the community in definitely (12). In fact, each wave behaved as a typical epidemic caused by a distinct variant of the virus. Wave 1 was

dominated by B.1 variant, wave 2 by B.1.36 variant, the wave 3 by Alpha/B1.1.7 and
Delta/B.1.617.2 variants, wave 4 had majority cases of the Delta/B.1.617.2 variant (28–
30) while wave 5 was driven by Omicron/BA.5.2.1.7 (4).

271 A key challenge faced by Pakistan at the beginning of the pandemic was that there was little prior experience with any pandemic outbreak of such level. Although disease 272 273 surveillance systems exist, they had not been scaled to manage case surveillance, hospital admissions, daily deaths, and eventually large-scale adult vaccination and event 274 tracking. Pakistan has a federal system of governance where provinces provide health 275 276 services while the federal ministry provides guidance and coordination. In addition, 277 considerable curative care is in the private sector. To address the potential difficulties in mounting a unified national response to the disease in the face of this diversity, a National 278 Action Plan for COVID-19 was formulated in March 2020 that placed the responsibility for 279 the national response in a National Coordination Committee (NCC) that was headed by 280 281 the Prime Minister and attended by all federal ministers. The NCC set national policy which was implemented by the National Command and Operation Centre (NCOC) that 282 was co-headed by the military and civilian leadership (32). The NCOC coordinated the 283 284 management of the extensive lockdowns, other key NPIs such as school closures, limited opening hours for essential businesses (examples of which included grocery stores and 285 pharmacies), closure of borders, cancellation of public events and social gatherings 286 (33,34). This was supported based on an elaborate data gathering and analysis system 287 that that guided daily decisions. 288

Wave 1 continued the longest and intervals became shorter between each successive wave. Each wave showed unique features, that were determined by the particular variant

that drove that wave, along with the larger context that included the type of the variant driving the wave, the extent and type of preventive interventions and eventually the availability of the vaccine.

294 Pakistan's response to COVID-19 evolved over time. For example, Wave 1 had the highest positivity rates and the longest duration, in part due to low initial rates of testing, 295 296 including very little contact tracing in the early days (35). As testing increased and mobility restrictions tightened, duration of Waves 2 and 3 became shorter. However, by the end 297 of the second wave, intervention fatigue had set in. Implementation was laxer, and these 298 factors contributed to more cases and deaths of any wave during Wave 3. Indeed, the 299 300 Oxford Health and Containment Index was significant only during Wave 1 in terms of preventing deaths. 301

In addition to preventive measures, the higher daily COVID-19 cases in waves 3, 4 and 302 5 may be attributed to highly transmissible Alpha (36,37), Delta (38,39) and Omicron (40) 303 variants, and to easing of severe restrictions such as lockdowns and school closures (41). 304 It is also possible that many cases were missed during Wave 1 due to limited testing. 305 However, the stability of daily testing in waves 3 to 5 suggests a stable equilibrium 306 between the testing system and how cases were being incident – the system was 307 capturing most of the cases from previously recognized populations and locations. It is 308 309 likely that undiagnosed cases and deaths were few, since as part of the national surveillance, teams kept abreast of burials in large and midsized towns and also 310 periodically canvased opinion of general practitioners about upsurges in respiratory 311 312 illnesses. On average, Pakistan had fewer cases per million population than neighboring

countries of India, Bangladesh, and Iran, as well as several of the developed countries(31).

315 As with prevention, clinical management of cases evolved over time. Initially most cases 316 were hospitalized as seen by the high case to hospitalization ratio - only 27% of admissions required oxygen 7% required ventilators during the Wave 1. In fact, there was 317 318 a correlation between deaths and oxygenation (which was mostly at hospitals) during waves 1 and 2, a pattern that was seen globally. However, with each succeeding wave, 319 use of oxygen increased while ventilators fluctuated within a narrow range, as was also 320 321 seen in India (52,53). Thus, even as COVID-19 hospitalizations peaked during Wave 3, hospitalization to case ratio increased, and average duration of hospitalization and the 322 use of hospitals for simple oxygenation fell, suggesting hospitals, ICU and ventilators, 323 were increasingly reserved only for the sickest (42). Deaths correlated best with a 21-day 324 delay model rather than a 28-day one, suggesting that most deaths happened early after 325 326 infection. Higher hospitalizations during the third wave may also have been attributed to the Alpha followed by Delta variants (43–45). By contrast the lower hospitalizations, 327 length of stay and mortality during the fifth wave may be attributed to the Omicron variant 328 329 that was seen worldwide (46,47), and specifically in South Africa (48) and Brazil (49) during the Omicron waves. Vaccination started halfway during wave 3 and more than half 330 331 of the eligible population was fully vaccinated (3) by the fifth wave, and may have contributed to lower hospitalizations in Wave 5. Unlike COVID-19 induced major 332 challenges to the healthcare capacity in various countries (50,51), Pakistan was able to 333 build healthcare resources capacity to keep pace with the pandemic. Ventilator and 334 oxygen utilization never exceeded 20% and 24% respectively in wave 3. 335

Vaccination drive started in Pakistan by the end of February 2021. Despite a slow start, vaccination picked up pace from 26,356 daily vaccinations in Wave 3 to 308,129 in the fourth wave as it was rolled-out to younger population and vaccine supply increased in the country. Average daily deaths did not reduce significantly due to vaccinations during the third and fourth waves (56,57) but showed marked reduction in hospitalizations and deaths towards the end of fourth and during the entire fifth wave (58).

From our regression model, we found that daily new COVID-19 cases were statistically 342 significant determinants of daily new deaths due to COVID-19. The association was also 343 observed from the third wave as both cumulative cases and deaths were the highest, 344 including the average daily deaths which were considerably higher than any other wave, 345 as seen in other countries (54). Secondly, daily new deaths due to COVID-19 increased 346 with patients on oxygenated beds while decreased with patients on ventilators in the initial 347 waves, potentially due to high patients load in hospitals, critical patients were put on 348 349 oxygen rather than ventilator. Fifth wave experienced the smallest number of daily COVID-19 deaths possibly because it was dominated by the Omicron variant (55). 350

# 351 **LIMITATIONS**

There are a number of limitations associated with the data used in this paper. While the official data used for the analysis are disaggregated by sub-national level, demographic disaggregation, such as age or gender, are not available. This limits the analysis in terms of the implication of gender and age on COVID-19 deaths. The national data is compiled by aggregating the numbers for each subnational unit in Pakistan. However, such an analysis would be too extensive to depict and therefore our analysis does not account for sub-national differences. It is possible that distinctive cultures, behaviors and differences in the stringency in enforcement of interventions vary between for regions and may in
 theory, influence the number of COVID-19 cases and deaths.

Similarly, data for hospitalizations is also unaccompanied by any information on comorbidities, as this information was not available beyond treating hospitals, losing a level of richness of analysis that includes such comorbidities. Also, data for daily new hospital admissions started becoming available towards the very end of wave 1. Consequently, the average length of hospital stay could not be calculated for this wave.

The official vaccination data available to us at the time of this analysis is not desegregated by the different types of available vaccines, for example Sinopharm, CanSino, Sputnik V and others. Differential impact of each vaccine on COVID-19 deaths in Pakistan would be informative. All of the above limitations notwithstanding, we are confident that this study provides crucial insights into the prevailing trends of COVID-19 in Pakistan in manner that is constructive.

# 372 CONCLUSION

373 COVID-19 management in Pakistan kept pace with the spread of the disease during five 374 distinct waves. We describe how these waves differed in terms of cases, hospitalizations 375 and deaths and analyze potential reasons for these differences. These lessons, as well 376 as limitations of our approach, provide important lessons for managing future pandemics.

## 377 **REFERENCES**

 Noreen N, Dil S, Ullah S, Niazi K, Naveed I, Khan NU, et al. Coronavirus disease (COVID-19) Pandemic and Pakistan; Limitations and Gaps. Limitations Gaps Glob Biosecurity [Internet]. 2020;1(3). Available from: https://jglobalbiosecurity.com/articles/63/galley/170/download/

- Babu GR, Khetrapal S, John DA, Deepa R, Narayan KMV. Pandemic
   preparedness and response to COVID-19 in South Asian countries. Int J Infect
   Dis [Internet]. 2021;104:169–74. Available from:
   https://doi.org/10.1016/j.ijid.2020.12.048
- NCOC. Vaccine Statistics [Internet]. 2022 [cited 2022 Feb 23]. p. NCOC Official
   Website. Available from: https://covid.gov.pk/vaccine-details
- Badar N, Ikram A, Salman M, Umair M, Rehman Z, Ahad A, et al. Genomic
   characterization of SARS-CoV-2 from Islamabad, Pakistan by Rapid Nanopore
   sequencing. Available from: https://doi.org/10.1101/2022.02.17.480826
- S. Coccia M. The impact of first and second wave of the COVID-19 pandemic in society: comparative analysis to support control measures to cope with negative effects of future infectious diseases. Environ Res [Internet].
   2021;197(April):111099. Available from: https://doi.org/10.1016/j.envres.2021.111099
- Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet [Internet]. 2021;397(10281):1265–75. Available from: http://dx.doi.org/10.1016/S0140-6736(21)00632-2
- Iftimie S, Lopez-Azcona AF, Vallverdu I, Hernandez-Flix S, De Febrer G, Parra S,
  et al. First and second waves of coronavirus disease-19: A comparative study in
  hospitalized patients in Reus, Spain. PLoS One. 2021;16(3 March 2021):1–13.
- Jalali SF, Ghassemzadeh M, Mouodi S, Javanian M, Kani MA, Ghadimi R, et al.
   Epidemiologic comparison of the first and second waves of coronavirus disease in
   Babol, North of Iran. Casp J Intern Med. 2020;11(2):S544–50.
- Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ,
  Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19
  vaccines: production, affordability, allocation, and deployment. Lancet. 2021 Mar
  13;397(10278):1023–34.
- Vanthomme K, Gadeyne S, Lusyne P, Vandenheede H. A population-based study
  on mortality among Belgian immigrants during the first COVID-19 wave in
  Belgium. Can demographic and socioeconomic indicators explain differential
  mortality? SSM Popul Heal [Internet]. 2021;14:100797. Available from:
  https://doi.org/10.1016/j.ssmph.2021.100797
- So MKP, Chu AMY, Tiwari A, Chan JNL. On topological properties of COVID-19:
  predicting and assessing pandemic risk with network statistics. Sci Rep [Internet].
  2021;11(1):1–14. Available from: https://doi.org/10.1038/s41598-021-84094-z
- 418 12. Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease
   419 epidemics: Implications for prevention strategies. J Infect Dis. 1996;174(SUPPL.
   420 2).
- 13. Sibiri H, Prah D, Zankawah SM. Containing the impact of COVID-19: Review of

Ghana's response approach. Heal Policy Technol [Internet]. 2021;10(1):13-5. 422 Available from: https://doi.org/10.1016/j.hlpt.2020.10.015 423 14. Olufadewa II, Adesina MA, Ekpo MD, Akinloye SJ, Iyanda TO, Nwachukwu P, et 424 al. Lessons from the coronavirus disease 2019 (COVID-19) pandemic response in 425 426 China, Italy, and the U.S.: a guide for Africa and low- and middle-income countries. Glob Heal J [Internet]. 2021;5(1):56–61. Available from: 427 428 https://doi.org/10.1016/j.glohj.2021.02.003 429 15. He D, Zhao S, Xu X, Lin Q, Zhuang Z, Cao P, et al. Low dispersion in the infectiousness of COVID-19 cases implies difficulty in control. BMC Public 430 Health. 2020;20(1):2-5. 431 432 16. Van Nguyen Q, Cao DA, Nghiem SH. Spread of COVID-19 and policy responses 433 in Vietnam: An overview. Int J Infect Dis [Internet]. 2021;103:157-61. Available from: https://doi.org/10.1016/j.ijid.2020.11.154 434 435 17. Sharma A, Borah SB, Moses AC. Responses to COVID-19: The role of governance, healthcare infrastructure, and learning from past pandemics. J Bus 436 Res [Internet]. 2021;122(102):597-607. Available from: 437 https://doi.org/10.1016/j.jbusres.2020.09.011 438 Seong H, Hyun HJ, Yun JG, Noh JY, Cheong HJ, Kim WJ, et al. Comparison of 18. 439 440 the second and third waves of the COVID-19 pandemic in South Korea: Importance of early public health intervention. Int J Infect Dis [Internet]. 441 2021;104:742-5. Available from: https://doi.org/10.1016/j.ijid.2021.02.004 442 OxCGRT. OxCGRT COVID Policy Tracker Data [Internet]. 2021. Available from: 443 19. https://github.com/OxCGRT/covid-policy-tracker/tree/master/data/timeseries 444 20. Hale T, Anania J, Angrist N, Boby T, Cameron-Blake E, Folco M Di, et al. 445 Variation in government responses to COVID-19, Version 12.0 [Internet]. BSG 446 Working Paper Series. 2021. Available from: 447 448 https://covidtracker.bsg.ox.ac.uk/stringency-scatter Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of 21. 449 mortality following COVID-19 infection. Lancet Infect Dis [Internet]. 450 451 2020;20(7):773. Available from: http://dx.doi.org/10.1016/S1473-3099(20)30195-X 22. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. 452 Causes of death and comorbidities in hospitalized patients with COVID-19. Sci 453 Rep [Internet]. 2021;11(1):1–9. Available from: https://doi.org/10.1038/s41598-454 021-82862-5 455 Marschner IC. Estimating age-specific COVID-19 fatality risk and time to death by 23. 456 comparing population diagnosis and death patterns: Australian data. BMC Med 457 Res Methodol [Internet]. 2021;21(1):1–10. Available from: 458 https://doi.org/10.1186/s12874-021-01314-w 459 Asirvatham ES, Sarman CJ, Saravanamurthy SP, Mahalingam P, 460 24. Maduraipandian S, Lakshmanan J. Who is dying from COVID-19 and when? An 461

462 463 464		Analysis of fatalities in Tamil Nadu, India. Clin Epidemiol Glob Heal [Internet]. 2021;9:275–9. Available from: https://www.sciencedirect.com/science/article/pii/S2213398420302189
465 466 467 468	25.	Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S- primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121–30.
469 470 471 472	26.	Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv [Internet]. 2021;(20):2021.09.03.21263062. Available from: http://medrxiv.org/content/early/2021/09/06/2021.09.03.21263062.abstract
473 474 475 476 477 478	27.	Liu X, Shaw RH, Stuart AS, Greenland M, Dinesh T, Provstgaard-Morys S, et al. Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non- Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine. SSRN Electronic Journal. 2021.
479 480 481 482	28.	Umair M, Ikram A, Rehman Z, Haider A, Badar N, Ammar M, et al. Genomic diversity of SARS-CoV-2 in Pakistan during fourth wave of pandemic. medRxiv [Internet]. 2021;92(51):2021.09.30.21264343. Available from: http://medrxiv.org/content/early/2021/10/03/2021.09.30.21264343.abstract
483 484 485 486	29.	Basheer A, Zahoor I. Genomic epidemiology of SARS-CoV-2 divulge B.1, B.1.36, and B.1.1.7 as the most dominant lineages in first, second, and third wave of SARS-CoV-2 infections in Pakistan. Microorganisms [Internet]. 2021 [cited 2022 Sep 21];9(12). Available from: https://doi.org/10.3390/microorganisms9122609
487 488 489 490	30.	Shakeel M, Irfan M, Nisa Z un, Farooq S, Ain N ul, Iqbal W, et al. Genome sequencing and analysis of genomic diversity in the locally transmitted SARS-CoV-2 in Pakistan. Transbound Emerg Dis [Internet]. 2022; Available from: http://tree.bio.ed.ac.uk/software/Fig.tree/
491 492 493	31.	Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19) [Internet]. OurWorldInData.org. 2020. Available from: https://ourworldindata.org/coronavirus
494 495 496 497	32.	National Institute of Health Pakistan. National Action Plan for Corona virus disease (COVID-19) Pakistan [Internet]. 2020. Available from: https://www.nih.org.pk/wp-content/uploads/2020/03/COVID-19-NAP-V2-13-March-2020.pdf
498 499 500 501 502	33.	Gul A. Pakistan Seals Borders, Shuts Schools, Bans Public Events Over Coronavirus. Voanews.com [Internet]. 2020 Mar 13;COVID-19 Pandemic. Available from: https://www.voanews.com/a/science-health_coronavirus- outbreak_pakistan-seals-borders-shuts-schools-bans-public-events- over/6185785.html


- So3 34. Chandir S, Siddiqi DA, Setayesh H, Khan AJ. Impact of COVID-19 lockdown on routine immunisation in Karachi, Pakistan. Lancet Glob Heal [Internet].
  So5 2020;8(9):e1118–20. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30290-4/fulltext
- 50835.Habib M, Abbas M. Facing the Threat of COVID-19 in Pakistan: A Nation's509Dilemma. Value Heal Reg issues. 2021 May;24:90–5.
- 36. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
  transmissibility of SARS-CoV-2 lineage B.1.1.7 in England The COVID-19
  Genomics UK (COG-UK) consortium. Nature [Internet]. 2021;593. Available from:
  https://doi.org/10.1038/s41586-021-03470-x
- 37. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al.
  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
  Science (80-) [Internet]. 2021;372(6538). Available from:
  http://science.sciencemag.org/
- 51838.Zhan Y, Yin H, Yin J-Y. (Delta) Variant of SARS-CoV-2: features, transmission519and potential strategies. Int J Biol Sci [Internet]. 2022;2022(5):1844–51. Available520from: https://www.ijbs.com//creativecommons.org/licenses/by/4.0/
- S21 39. Kumar S, Tripathi V, Zhang J, Hu Z, Huang X, Fu S, et al. Differences in Clinical
  Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected
  Patients. Front Med | www.frontiersin.org [Internet]. 2019;1:792135. Available
  from: www.frontiersin.org
- 40. Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the
   highly mutated SARS-CoV-2 Omicron variant. 2022; Available from:
   https://www.gisaid.org/
- 41. Provinces announce easing lockdown even as Pakistan witnesses record rise in coronavirus cases [Internet]. DAWN. 2020 [cited 2022 Aug 1]. Available from: https://www.dawn.com/news/1555575
- Karagiannidis C, Windisch W, McAuley DF, Welte T, Busse R. Major differences
  in ICU admissions during the first and second COVID-19 wave in Germany
  [Internet]. Vol. 9, The Lancet Respiratory Medicine. 2021 [cited 2022 Oct 7]. p.
  e47–8. Available from: https://doi.
- Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al.
  Hospital admission and emergency care attendance risk for SARS-CoV-2 delta
  (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.
  Lancet Infect Dis [Internet]. 2021; Available from:
  https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00475-
- 539 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00475-540 8/fulltext
- 541 44. Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the Delta
  542 Variant B.1.617.2 COVID-19. Clin Pr [Internet]. 2021;11:778–84. Available from:
  543 https://doi.org/10.3390/clinpract11040093

- Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in
  Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
  Lancet [Internet]. 2021 Jun 26 [cited 2022 Oct 7];397(10293):2461–2. Available
  from: http://www.thelancet.com/article/S0140673621013581/fulltext
- 548
  548
  549
  550
  550
  550
  550
  551
  551
  552
  553
  554
  554
  554
  555
  555
  555
  556
  557
  557
  558
  559
  559
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
  550
- 551 Available from: https://pubmed.ncbi.nlm.nih.gov/35246846/
- 47. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2
  Omicron Variant Severity in Ontario, Canada. JAMA [Internet]. 2022 Apr 5 [cited
  2022 Oct 7];327(13):1286–8. Available from:
  https://iamanetwork.com/iournals/iama/fullarticle/2789408
- 555 https://jamanetwork.com/journals/jama/fullarticle/2789408
- 48. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B.
  Characteristics and Outcomes of Hospitalized Patients in South Africa during the
  COVID-19 Omicron wave Compared with Previous waves. JAMA J Am Med
  Assoc. 2022 Feb 8;327(6):583–4.
- Martins-Filho PR, de Souza Araújo AA, Quintans-Júnior LJ, Soares BDS, Barboza
  W de S, Cavalcante TF, et al. Dynamics of hospitalizations and in-hospital deaths
  from COVID-19 in northeast Brazil: a retrospective analysis based on the
  circulation of SARS-CoV-2 variants and vaccination coverage. Epidemiol Health
  [Internet]. 2022 [cited 2022 Oct 7];44:e2022036. Available from:
  https://pubmed.ncbi.nlm.nih.gov/35413166/
- 566 50. Mateen BA, Wilde H, Dennis JM, Duncan A, Thomas N, McGovern A, et al.
  567 Hospital bed capacity and usage across secondary healthcare providers in
  568 England during the first wave of the COVID-19 pandemic: a descriptive analysis.
  569 BMJ Open [Internet]. 2021 Jan 26 [cited 2022 Oct 7];11(1). Available from:
  570 https://pubmed.ncbi.nlm.nih.gov/33500288/
- 571 51. Mahendradhata Y, Andayani NLPE, Hasri ET, Arifi MD, Siahaan RGM, Solikha
  572 DA, et al. The Capacity of the Indonesian Healthcare System to Respond to
  573 COVID-19. Front Public Heal. 2021 Jul 7;9:887.
- 574 52. Kumar G, Mukherjee A, Sharma RK, Menon GR, Sahu D, Wig N, et al. Clinical
  575 profile of hospitalized COVID-19 patients in first & second wave of the pandemic:
  576 Insights from an Indian registry based observational study. Indian J Med Res
  577 [Internet]. 2021 May 1 [cited 2022 Oct 7];153(5–6):619. Available from:
  578 /pmc/articles/PMC8555588/
- 579 53. Budhiraja S, Indrayan A, Aggarwal M, Jha V, Jain D, Tarai B, et al. Differentials in
  580 the characteristics of COVID-19 cases in wave-1 and wave-2 admitted to a
  581 network of hospitals in North India [Preprint]. medRxiv [Internet]. 2021 Jun 27
  582 [cited 2022 Oct 7];2021.06.24.21259438. Available from:
- 583 https://www.medrxiv.org/content/10.1101/2021.06.24.21259438v1
- 584 54. Anscombe C, Lissauer S, Thole H, Rylance J, Dula D, Menyere M, et al. A

- comparison of four epidemic waves of COVID-19 in Malawi; an observational
   cohort study [Preprint]. medRxiv [Internet]. 2022 [cited 2022 Oct 7]; Available
   from: /pmc/articles/PMC9298135/
- 588 55. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al.
  589 Decreased severity of disease during the first global omicron variant covid-19
  590 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis [Internet].
  591 2022 Mar 1 [cited 2022 Oct 7];116:38–42. Available from:
- 592 https://pubmed.ncbi.nlm.nih.gov/34971823/
- 593 56. Jabłońska K, Aballéa S, Toumi M. The real-life impact of vaccination on COVID-594 19 mortality in Europe and Israel. Public Health. 2021 Sep 1;198(May):230–7.
- 595 57. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
  596 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl
  597 J Med [Internet]. 2021 Aug 12 [cited 2022 Oct 7];385(7):585–94. Available from:
  598 https://pubmed.ncbi.nlm.nih.gov/34289274/
- 58. Xavier CR, Oliveira RS, Vieira V da F, Lobosco M, Dos Santos RW.
  Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa, Germany, and Brazil. BioTech [Internet]. 2022 Jun 1 [cited 2022 Oct 7];11(2).
  Available from: /pmc/articles/PMC9264399/
- 604

# 605 List of Legends

- **Table 1. Augmented Dicky-Fuller tests for unit roots**
- 607 Table 2. Descriptive characteristics of each COVID-19 wave
- Table 3. Ordinary least squares (OLS) regression results for COVID-19 deaths
- **Figure 1. COVID-19 waves and daily new cases**
- 610 S1 Table. Calculated ratio variables and their descriptions



# Figure